ArticleCureus2025
Emerging Manifestations of Cesarean Scar Defect in the Reproductive-Age Group.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCesarean scar defect (CSD), also referred to as isthmocele or niche, has emerged as a significant gynecological issue among reproductive-age women, attributed to rising cesarean delivery rates and improved imaging modalities. It often manifests as abnormal uterine bleeding (AUB), pelvic pain, and infertility. This study aimed to assess the clinical profile, imaging characteristics, and reproductive associations of CSD in women of reproductive age. MATERIALS AND
methodsThis cross-sectional study was conducted in the Department of Obstetrics and Gynecology from July 2022 to December 2023. Women aged 20-45 years with a history of cesarean delivery presenting with menstrual irregularities, pelvic pain, or infertility were evaluated using transvaginal sonography (TVS; GE Voluson E8, GE Healthcare, Chicago, IL, USA). Cases suspected of CSD underwent confirmation with saline infusion sonohysterography (GE Healthcare, Chicago, IL, USA) or hysteroscopy (Karl Storz GmbH & Co. KG, Tuttlingen, Germany). Clinical features, imaging findings, and reproductive outcomes were analyzed using SPSS Statistics version 24.0 (IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.), with p ≤ 0.05 considered statistically significant.
resultsA total of 100 women were included, with a mean age of 31.6 ± 4.2 years. AUB was the most common symptom, 78 (78%), followed by pelvic pain, 46 (46%), and secondary infertility, 39 (39%). TVS identified CSD in 89 (89%) of cases; it was confirmed hysteroscopically in 81 (81%). Women with ≥2 previous cesarean sections had significantly deeper defects (p = 0.02). A niche depth >3 mm, as defined in prior literature, was significantly associated with secondary infertility (p = 0.01). Emergency cesarean delivery correlated with irregular niche formation (p = 0.03).
conclusionsCSD is an underdiagnosed but clinically important condition contributing to gynecological morbidity and infertility. Early recognition through imaging and heightened clinical awareness can improve reproductive outcomes and prevent complications in subsequent pregnancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.